Sa1887 PROACTIVE DRUG MONITORING IS ASSOCIATED WITH HIGHER PERSISTENCE TO INFLIXIMAB AND ADALIMUMAB TREATMENT AND LOWER HEALTHCARE UTILIZATION COMPARED TO REACTIVE AND CLINICAL MONITORING